Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Suchard

Showing results (51-60 of 68) with videos related to

Pageof 7
Sort By:
Journal of Clinical Immunology|March 5, 2009
Abatacept does not induce direct gene expression changes in antigen-presenting cellsJulie A Carman, Patricia M Davis, Wen-Pin Yang, et al.
The Journal of Experimental Medicine|February 5, 2014
2B4 (CD244) induced by selective CD28 blockade functionally regulates allograft-specific CD8+ T cell responsesDanya Liu, Scott M Krummey, I Raul Badell, et al.
Journal of Immunology (Baltimore, Md. : 1950)|March 2, 2010
An LFA-1 (alphaLbeta2) small-molecule antagonist reduces inflammation and joint destruction in murine models of arthritisSuzanne J Suchard, Dawn K Stetsko, Patricia M Davis, et al.
Bioorganic & Medicinal Chemistry Letters|February 13, 2007
Design of LFA-1 antagonists based on a 2,3-dihydro-1H-pyrrolizin-5(7aH)-one scaffoldDharmpal S Dodd, Steven Sheriff, ChiehYing J Chang, et al.
Journal of Immunology (Baltimore, Md. : 1950)|October 2, 2013
A monovalent anti-human CD28 domain antibody antagonist: preclinical efficacy and safetySuzanne J Suchard, Patricia M Davis, Selena Kansal, et al.
Journal of Molecular Biology|May 25, 2016
Functional Antagonism of Human CD40 Achieved by Targeting a Unique Species-Specific EpitopeAaron P Yamniuk, Anish Suri, Stanley R Krystek, et al.
The Journal of Pharmacology and Experimental Therapeutics|October 8, 2015
Integrated Pharmacokinetic/Pharmacodynamic Analysis for Determining the Minimal Anticipated Biological Effect Level of a Novel Anti-CD28 Receptor Antagonist BMS-931699Zheng Yang, Haiqing Wang, Theodora W Salcedo, et al.
Frontiers in Immunology|August 21, 2018
Circulating T Cell Subpopulations Correlate With Immune Responses at the Tumor Site and Clinical Response to PD1 Inhibition in Non-Small Cell Lung CancerNataly Manjarrez-Orduño, Laurence C Menard, Selena Kansal, et al.
JCI Insight|October 5, 2016
B cells from African American lupus patients exhibit an activated phenotypeLaurence C Menard, Sium Habte, Waldemar Gonsiorek, et al.
Bioorganic & Medicinal Chemistry Letters|February 3, 2005
De novo design, synthesis, and in vitro activity of LFA-1 antagonists based on a bicyclic[5.5]hydantoin scaffoldDominique Potin, Michele Launay, Eric Nicolai, et al.
Pageof 7

Showing results (51-60 of 68) with videos related to

Sort By:
Pageof 7
Journal of Clinical Immunology|March 5, 2009
Abatacept does not induce direct gene expression changes in antigen-presenting cellsJulie A Carman, Patricia M Davis, Wen-Pin Yang, et al.
The Journal of Experimental Medicine|February 5, 2014
2B4 (CD244) induced by selective CD28 blockade functionally regulates allograft-specific CD8+ T cell responsesDanya Liu, Scott M Krummey, I Raul Badell, et al.
Journal of Immunology (Baltimore, Md. : 1950)|March 2, 2010
An LFA-1 (alphaLbeta2) small-molecule antagonist reduces inflammation and joint destruction in murine models of arthritisSuzanne J Suchard, Dawn K Stetsko, Patricia M Davis, et al.
Bioorganic & Medicinal Chemistry Letters|February 13, 2007
Design of LFA-1 antagonists based on a 2,3-dihydro-1H-pyrrolizin-5(7aH)-one scaffoldDharmpal S Dodd, Steven Sheriff, ChiehYing J Chang, et al.
Journal of Immunology (Baltimore, Md. : 1950)|October 2, 2013
A monovalent anti-human CD28 domain antibody antagonist: preclinical efficacy and safetySuzanne J Suchard, Patricia M Davis, Selena Kansal, et al.
Journal of Molecular Biology|May 25, 2016
Functional Antagonism of Human CD40 Achieved by Targeting a Unique Species-Specific EpitopeAaron P Yamniuk, Anish Suri, Stanley R Krystek, et al.
The Journal of Pharmacology and Experimental Therapeutics|October 8, 2015
Integrated Pharmacokinetic/Pharmacodynamic Analysis for Determining the Minimal Anticipated Biological Effect Level of a Novel Anti-CD28 Receptor Antagonist BMS-931699Zheng Yang, Haiqing Wang, Theodora W Salcedo, et al.
Frontiers in Immunology|August 21, 2018
Circulating T Cell Subpopulations Correlate With Immune Responses at the Tumor Site and Clinical Response to PD1 Inhibition in Non-Small Cell Lung CancerNataly Manjarrez-Orduño, Laurence C Menard, Selena Kansal, et al.
JCI Insight|October 5, 2016
B cells from African American lupus patients exhibit an activated phenotypeLaurence C Menard, Sium Habte, Waldemar Gonsiorek, et al.
Bioorganic & Medicinal Chemistry Letters|February 3, 2005
De novo design, synthesis, and in vitro activity of LFA-1 antagonists based on a bicyclic[5.5]hydantoin scaffoldDominique Potin, Michele Launay, Eric Nicolai, et al.
Pageof 7